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Background
Most studies published to date have shown an increase
in cardiovascular risk (CVR) in patients with HIV infec-
tion attributed to both viral activity and antiretroviral
therapy (ART). Metabolic syndrome (MS) and insulin
resistance syndrome (IR) may represent useful clinical
tools for early identification of patients with increased
CVR. Our study aimed to evaluate CVR in HIV-infected
patients undergoing ART, to identify risk factors for car-
diovascular events and to assess the correlations
between the presence of MS, IR and CVR.
Methods
The diagnosis of MS was established using the Interna-
tional Diabetes Federation (IDF) and the American
Heart Association/National Heart, Lung, and Blood
Institute (AHA/NHLBI) harmonized criteria. Quantita-
tive Insulin Sensitivity Check Index (QUICKI) values
were used to quantify IR. CVR was assessed based on
Framingham cardiovascular risk score.
Results
We enrolled 103 patients, including 60 males (58.3%)
and 43 females (41.7%). The mean age was 32.3±13.3
years (range: 13-65 years). The median Framingham
score was 1.2% (IQR=5.8%). Most patients (81.63%) had
a low CVR (below 10%) and 18.37% had Framingham
score values above 10%. MS and IR prevalences were
16.9% and 61.2%, respectively. CVR in the general popu-
lation is primarily dependent on age. This observation
was valid for our group: the median age was 24 years in
people with low CVR, compared with 50 years for those
with Framingham score above 10% (p=0.000). None of
the antiretroviral drug classes significantly influenced
CVR.
MS patients were approximately five times more likely
to have a medium/high CVR (OR 5.3, p=0.000). IR and
MS were not significantly correlated (OR 0.8, p=0.642).
Conclusions
Approximately one fifth of our patients had a medium
or high CVR, a significant value, given the young age of
those enrolled. Similar to the general population, the
most important risk factor for increased CVR was age.
The presence of MS and CVR were strongly correlated,
suggesting that using MS criteria for increased CVR
screening is useful in these patients.
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